A Phase 3 interventional study of Ilaprazole and Lansoprazole in Peptic Ulcer, sponsored by Il-Yang Pharm. Co., Ltd.. Active, not recruiting at 2 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Il-Yang Pharm. Co., Ltd. · Phase 3, Interventional, and Prevention
To demonstrate the non-inferiority of Ilaprazole 10 mg to the active control in prevention of NSAIDs-associated peptic ulcer, as assessed by the proportion of subjects with peptic ulcer by Week 24
Not provided
146 studies on the registry are indexed under Peptic Ulcer; 25 are open to participants now.
This study's planned enrollment of 416 is above the median of 165 across 105 interventional studies indexed under Peptic Ulcer.
Browse Peptic Ulcer studies →Il-Yang Pharm. Co., Ltd. is the lead sponsor of 34 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Take Ilaprazole 10 mg 1 tablet + Placebo of Lansoprazole 15 mg 1 capsule by mouth, with water, once daily.
Drug: Ilaprazole · Drug: Lansoprazole Placebo
Take Lansoprazole 15 mg 1 capsule + Placebo of Ilaprazole 10 mg 1 tablet by mouth, with water, once daily.
Drug: Lansoprazole · Drug: Ilaprazole Placebo
Ilaprazole 10 mg
Also known as: Noltec(the brand name)
Lansoprazole 15 mg
Also known as: Lanston(the brand name)
Placebo of Ilaprazole 10 mg
Also known as: Ilaprazole Placebo-matching tablet
Placebo of Lansoprazole 15 mg
Also known as: Lansoprazole Placebo-matching tablet
Ilaprazole, Lansoprazole peptic ulcer
Proportion of subjects with newly developed peptic ulcer until Week 24 after the IP treatment
Time frame: at 24 weeks
Ilaprazole, Lansoprazole peptic ulcer
Proportion of subjects with newly developed peptic ulcer until Week 12 after the IP treatment
Time frame: at 12 weeks
Ilaprazole, Lansoprazole GI bleeding
Proportion of subjects with upper GI bleeding by Week 12 and Week 24 after the IP treatment
Time frame: at 12, 24 weeks
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ilaprazole